Monday, March 18, 2019 2:30:57 PM
I don't know what may have been told the visitor to the company about where things are WRT patent approval, but clearly until they happen everything is up in the air. I believe trials to date are being run cheaply as the Israeli hospitals doing the work are willing to take some royalty income rather than being paid for their services. That's fine for Phase 1, but when you go to Phase 2 and beyond the trials should expand to multiple locations, some outside of Israel, and hopefully some sites here in the U.S. The cost is dramatically higher, and the protocol should be documented on clinical trials, or a similar database in order to attract the needed patients.
To really move on, we need the jury to come in positively for at least the drugs where Phase 2 is being planned. Without that, I believe the best we'll see is a series of delays and promises unmet.
Gary
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM